Diagnostic utility of serum dipeptidyl peptidase (DPP- IV) /CD26 as a serum marker in Egyptian patients with colorectal cancer

J Immunoassay Immunochem. 2020 Jul 3;41(4):729-744. doi: 10.1080/15321819.2020.1744642. Epub 2020 Mar 29.

Abstract

Background: Colorectal cancer (CRC) is considered a major cause of morbidity and mortality in Egypt. Colonoscopy is the standard for detection of lesions. The combination of screening methods is effective. Decrease and loss of DPP-IV/CD26 expression and activity are found in microenvironments of specific tumors which are related to impaired immune functions.

Aim of the work: To study sCD26 as a noninvasive test in Egyptian patients with CRC as well as their correlation to CEA, CA 19-9 & other -biochemical parameters and determine the possibility to use it as a diagnostic tool for CRC.

Patients and methods: This study included 40 patients divided into two groups: group I: comprised 20 patients with CRC, group II: comprised 20 patients with other colorectal disease together with 20 healthy control.

Results: There was highly significant decrease in sCD26 in group I in comparison to group II and III. CD26 at cutoff 4.69 mg/mL, its sensitivity was 85% and its specificity was 87.5%.

Conclusion: CD26 is involved in the pathogenesis of colorectal diseases; sCD26 is diminished in CRC patients suggesting the potential utility of a sCD26 for diagnosis.

Keywords: Colorectal cancer; diagnostic biomarker; dpp IV/CD26.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / diagnosis*
  • Dipeptidyl Peptidase 4 / blood*
  • Egypt
  • Female
  • Humans
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Biomarkers, Tumor
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4